FindTrial
Sign In

Effect of Sacubitril/ Valsartan and ramipril on coronary bypass surgery patient.

A comparative study of efficacy and safety of Sacubitril/ Valsartan combination with Ramipril on left ventricular ejection fraction in post coronary artery bypass grafting (CABG) patients.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/02/023488
Enrollment
50
Registered
2020-02-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: I257- Atherosclerosis of coronary arterybypass graft(s) and coronary artery of transplanted heart with angina pectoris

Interventions

Intervention1: Sacubitril/Valsartan combination: Subjects receive Sacubitril/Valsartan combination tablet (Sacubitril 24mg/Valsartan 26mg) twice daily for 3 months post operative period. Control Inter

Sponsors

Soumitra Mandal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: I. Patients planning for CABG II. Age in between 30 to 70 years. III. New York Heart association (NYHA) functional class II-IV symptoms for heart failure. IV. Ejection fraction of 40% or less.

Exclusion criteria

Exclusion criteria: I. Symptomatic hypotension (Systolic blood pressure II. Estimated glomerular filtration rate III. Hypersensitivity to study medication. IV. Any history of angioedema. V. Concomitant use with any drug formulation containing an angiotensin-converting enzyme inhibitor.

Design outcomes

Primary

MeasureTime frame
1. The change in ejection fraction in the both group compare to baseline at 30 days and 90 days. 2. Change in left ventricular end systolic diameter, left ventricular end-diastolic diameter, LV mass (reverse remodeling parameters) in the both group compare to baseline at 30 days and 90 days. Timepoint: Both group compare to baseline at 30 days and 90 days post operative days.—

Secondary

MeasureTime frame
1. Proportion of patients died due to cardiovascular cause in each group. 2. Proportion of patientsâ?? hospitalization due to cardiovascular cause in each group. 3. Proportion of patients died due to noncardiovascular cause in each group. 4. Proportion of patientsâ?? hospitalization due to noncardiovascular cause in each group. Timepoint: Both group compare to baseline at 30 days and 90 days post operative days.—

Countries

India

Contacts

Public ContactARUNA DONEPUDI

Nizams Institute of Medical Sciences

Adonepudi@yahoo.co.in9848923036

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026